ANTENGENE-B(06996): XEVIO approved in Malaysia for a new indication in the treatment of diffuse large B-cell lymphoma.

06:49 17/12/2025

Dexy Biomedical-B (06996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental new drug application (sNDA) for Xyvio (selinexor), approving Xyvio for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systemic therapy and are not eligible for autologous stem cell transplantation.

ANTENGENE-B (06996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental new drug application (sNDA) for XEVIOUS (selinexor) to be marketed. XEVIOUS has been approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systemic therapy and are not eligible for autologous stem cell transplant.

Alphabet (GOOGL.US) subsidiary, the self-driving giant Waymo, is seeking funding of over $15 billion, with a valuation approaching $100 billion.

GMTEight List of A-share restricted sales and lifting restrictions | December 17th

Zhongneng Holdings (00228) will be temporarily suspended from trading starting on December 17th until the publication of inside information.

Alphabet (GOOGL.US) subsidiary, the self-driving giant Waymo, is seeking funding of over $15 billion, with a valuation approaching $100 billion.

GMTEight List of A-share restricted sales and lifting restrictions | December 17th

Zhongneng Holdings (00228) will be temporarily suspended from trading starting on December 17th until the publication of inside information.